Cargando…
SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, long-acting glucocorticoids (GCs) and/or multiple daily dose short-acting GCs are historically suggested to disease management. However, these treatment strategies are generally associated with GC overexposure, w...
Autores principales: | Simeoli, Chiara, Ferrigno, Rosario, Angellotti, Domenico, Iacuaniello, Davide, Pivonello, Claudia, Negri, Mariarosaria, Di Gennaro, Gilda, De Martino, Maria Cristina, Colao, Annamaria, Pivonello, Rosario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552856/ http://dx.doi.org/10.1210/js.2019-SUN-358 |
Ejemplares similares
-
Cushing’s disease: adrenal steroidogenesis inhibitors
por: Pivonello, Rosario, et al.
Publicado: (2022) -
The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
por: Simeoli, C., et al.
Publicado: (2019) -
SUN-398 A Case of Bilateral Testicular Adrenal Rest Tumors in a Patient with Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency
por: Alsaeed, Abdulghani
Publicado: (2019) -
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
por: Pivonello, Rosario, et al.
Publicado: (2020) -
Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)